Clinical Trial Update: Study of Mogamulizumab + Docetaxel in Subjects With Non-small Cell Lung Cancer [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating mogamulizumab in combination with docetaxel for non-small cell lung cancer; the study has completed and results were posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• Mogamulizumab (mogamulizumab)

Snippet

Sponsor: Kyowa Kirin, Inc. | Conditions: Non-Small Cell Lung Cancer | Phase 1 | Status: COMPLETED | Results posted: 2018-11-30